Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CHD
MCID: CRN300
MIFTS: 59

Coronary Heart Disease 1 (CHD)

Categories: Blood diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Coronary Heart Disease 1

About this section

MalaCards integrated aliases for Coronary Heart Disease 1:

Name: Coronary Heart Disease 1 57 29
Coronary Heart Disease 57 75 29 55 6 63 17 72
Coronary Heart Disease, Susceptibility to, 1 57 72
Coronary Heart Disease, Susceptibility to 57 13
Heart, Coronary, Disease, Susceptibility to, Type 1 40
Coronary Arteriosclerosis 72
Coronary Artery Disease 72
Chds1 57
Chd 48

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 57 607339
UMLS 72 C0010054 C0010068 C1846418 more
Sources

Summaries for Coronary Heart Disease 1

About this section
PubMed Health : 63 About coronary heart disease: Coronary heart disease (CHD) is a disease in which a waxy substance called plaque (plak) builds up inside the coronary arteries. These arteries supply oxygen-rich blood to your heart muscle. When plaque builds up in the arteries, the condition is called atherosclerosis (ATH-er-o-skler-O-sis). The buildup of plaque occurs over many years.

MalaCards based summary : Coronary Heart Disease 1, also known as coronary heart disease, is related to diabetes mellitus and diabetes mellitus, noninsulin-dependent, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Coronary Heart Disease 1 is APOC3 (Apolipoprotein C3), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Nitric Oxide and Ethinyl Estradiol have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes.

Wikipedia : 75 Coronary artery disease (CAD), also known as ischemic heart disease (IHD), involves the reduction of... more...

More information from OMIM: 607339
Sources

Related Diseases for Coronary Heart Disease 1

About this section

Diseases in the Coronary Heart Disease 1 family:

Coronary Heart Disease 3 Coronary Heart Disease 2
Coronary Heart Disease 4 Coronary Heart Disease 5
Coronary Heart Disease 7 Coronary Heart Disease 8
Coronary Heart Disease 9 Coronary Heart Disease 6

Diseases related to Coronary Heart Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 669)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus 32.2 SOCS1 MIR155 MIR145 MIR140 CDKN2B-AS1
2 diabetes mellitus, noninsulin-dependent 32.2 WFDC21P SOCS1 MIR126 GAS5 CDKN2B-AS1 APOC3
3 gastric cancer 31.1 MIR145 HOTTIP H19 GAS5 CDKN2B-AS1 CDKN2B
4 endometriosis 30.9 MIR145 MIR126 H19 CDKN2B-AS1
5 esophageal cancer 30.9 MIR126 HOTTIP H19 GAS5 CDKN2B-AS1 CDKN2B
6 prostate cancer 30.9 MIR182 MIR145 MIR126 IGF2-AS HOTTIP H19
7 prostate disease 30.9 IGF2-AS H19 GAS5 CDKN2B-AS1
8 colorectal cancer 30.8 SOCS1 MIR182 MIR155 MIR145 MIR140 MIR126
9 lung cancer 30.7 MIR182 MIR155 MIR145 MIR140 MIR126 IGF2-AS
10 bladder cancer 30.6 MIR145 H19 GAS5 CDKN2B-AS1 CDKN2A
11 ovarian cancer 30.6 MIR182 MIR155 MIR145 MIR140 MIR126 H19
12 hepatocellular carcinoma 30.4 SOCS1 MIR182 MIR155 MIR145 MIR126 IGF2-AS
13 hyperlipoproteinemia, type iii 12.1
14 coronary artery anomaly 11.9
15 angina pectoris 11.8
16 coronary heart disease 2 11.7
17 coronary heart disease 4 11.7
18 coronary heart disease 5 11.7
19 hypercholesterolemia, familial, 1 11.7
20 hyperlipidemia, familial combined, 3 11.7
21 coronary heart disease 3 11.6
22 coronary heart disease 7 11.6
23 coronary heart disease 8 11.6
24 coronary heart disease 9 11.6
25 coronary heart disease 6 11.6
26 familial hypercholesterolemia 11.6
27 cardiac arrest 11.6
28 abdominal obesity-metabolic syndrome 1 11.5
29 alopecia, androgenetic, 1 11.5
30 hypoalphalipoproteinemia, primary, 1 11.5
31 hyperlipidemia, familial combined, 1 11.5
32 cleft palate, cardiac defect, genital anomalies, and ectrodactyly 11.4
33 high density lipoprotein cholesterol level quantitative trait locus 1 11.3
34 total anomalous pulmonary venous return 1 11.3
35 8p23.1 duplication syndrome 11.1
36 lipid metabolism disorder 11.0
37 intermediate coronary syndrome 11.0
38 atherosclerosis susceptibility 10.9
39 ischemia 10.9
40 oral squamous cell carcinoma 10.9 MIR155 MIR140 MIR126 H19
41 pancreatic ductal adenocarcinoma 10.9 MIR155 MIR145 HOTTIP H19
42 vascular disease 10.9
43 body mass index quantitative trait locus 1 10.9
44 kidney cancer 10.9 MIR182 MIR17 MIR126 H19 GAS5
45 thyroid cancer, nonmedullary, 1 10.8 MIR155 HOTTIP H19 GAS5
46 melanoma-pancreatic cancer syndrome 10.8 CDKN2B-AS1 CDKN2A
47 malignant glioma 10.8 HOTTIP GAS5 CDKN2B-AS1
48 osteogenic sarcoma 10.8 MIR140 HOTTIP H19 GAS5 CDKN2B-AS1
49 coronary stenosis 10.8
50 laryngeal squamous cell carcinoma 10.8 H19 CDKN2B-AS1 CDKN2A

Graphical network of the top 20 diseases related to Coronary Heart Disease 1:



Diseases related to Coronary Heart Disease 1
Sources

Symptoms & Phenotypes for Coronary Heart Disease 1

About this section

Clinical features from OMIM:

607339

UMLS symptoms related to Coronary Heart Disease 1:


tremor, angina pectoris, edema, chest pain, equilibration disorder, substernal pain
Sources

Drugs & Therapeutics for Coronary Heart Disease 1

About this section

PubMed Health treatment related to Coronary Heart Disease 1: 63

Treatments for coronary heart disease (CHD) include lifestyle changes, medicines, and medical procedures. Treatment goals may include: Relieving symptoms.Reducing risk factors in an effort to slow, stop, or reverse the buildup of plaque.Lowering the risk of blood clots forming. (Blood clots can cause a heart attack.)Widening or bypassing clogged arteries.Preventing complications of CHD.

Drugs for Coronary Heart Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 963)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
3
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
4
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
5
Coal tar Approved Phase 4 8007-45-2
6
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
7
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
8
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
9
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
10
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
11
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
12
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
15
Eplerenone Approved Phase 4 107724-20-9 150310 443872
16
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
17
Ticlopidine Approved Phase 4 55142-85-3 5472
18
Probucol Approved, Investigational Phase 4 23288-49-5 4912
19
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
20
Dobutamine Approved Phase 4 34368-04-2 36811
21
Digoxin Approved Phase 4 20830-75-5 30322 2724385
22
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
23
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
24
Cosyntropin Approved Phase 4 16960-16-0 16129617
25
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
26
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
27
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
28
Etomidate Approved Phase 4 33125-97-2 36339 667484
29
Histamine Approved, Investigational Phase 4 51-45-6 774
30
Ranitidine Approved Phase 4 66357-35-5, 66357-59-3 3001055
31
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
32
Polyestradiol phosphate Approved Phase 4 28014-46-2
33
Nifedipine Approved Phase 4 21829-25-4 4485
34
Propranolol Approved, Investigational Phase 4 525-66-6 4946
35
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
36
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
37
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
38
Famotidine Approved Phase 4 76824-35-6 3325
39
Norepinephrine Approved Phase 4 51-41-2 439260
40
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
41
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
42
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
43
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
44
Edoxaban Approved Phase 4 480449-70-5
45
Remifentanil Approved Phase 4 132875-61-7 60815
46
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
47
Saxagliptin Approved Phase 4 361442-04-8 11243969
48
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
49
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
50
Citalopram Approved Phase 4 59729-33-8 2771

Interventional clinical trials:

(show top 50) (show all 6247)
# Name Status NCT ID Phase Drugs
1 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
2 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
3 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
4 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
5 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
6 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
7 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
8 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
9 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
10 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
11 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
12 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4
13 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
14 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
15 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
16 Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings Unknown status NCT01068106 Phase 4
17 Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up. Unknown status NCT00888758 Phase 4
18 Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
19 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
20 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
21 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
22 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
23 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
24 Comparison of Efficacy and Safety of Ivabradine Versus Metoprolol for Controlling Heart Rate Prior to 640-Slice Computed Tomographic Angiography in Elective Patients Unknown status NCT01755663 Phase 4 Ivabradine and Metoprolol
25 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
26 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
27 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
28 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
29 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
30 Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial Unknown status NCT01810224 Phase 4
31 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
32 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
33 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
34 Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study Unknown status NCT02154295 Phase 4
35 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
36 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
37 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
38 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
39 Studies of Application of Combined General Anesthesia and Bilateral Thoracic Paravertebral Block by Ropivacaine in Patients Undergoing Off-pump Coronary Artery Bridge Graft - a Random Double Blind Controlled Study Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
40 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
41 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
42 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
43 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
44 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
45 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
46 Impact of Periodontal Therapy in Flow-mediated Dilation and Serum Levels of Cardiovascular Risk Biomarkers in Coronary Artery Disease Patients: 12 Months Randomized Controlled Trial Unknown status NCT01609725 Phase 4
47 Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
48 The 001-DIOR Multicenter Registry (A Novel Percutaneous Coronary Intervention With the New Paclitaxel-eluting Balloon DIOR in Ostial Bifurcated Lesions) Unknown status NCT01375465 Phase 4
49 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
50 Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting: A Double-blind, Placebo-controlled, Randomized Trial Unknown status NCT03049085 Phase 4 Aspirin;vitamin C

Search NIH Clinical Center for Coronary Heart Disease 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Amlodipine
Ammonia N-13
atorvastatin
Atorvastatin calcium
cerivastatin
Cerivastatin sodium
Cholestyramine Resin
Clofibrate
colesevelam
Colesevelam hydrochloride
Colestipol
Colestipol Hydrochloride
Dextrothyroxine
Dextrothyroxine Sodium
Dipyridamole
Dobutamine
eptifibatide
Fenofibrate
Fish Liver Oils
Fludeoxyglucose (18F)
fluvastatin
Fluvastatin
Fluvastatin sodium
Gemfibrozil
Gemfibrozil
Isosorbide
Isosorbide dinitrate
Isosorbide Dinitrate
Isosorbide Mononitrate
Lovastatin
Lovastatin
Pravastatin
Pravastatin
Pravastatin Sodium
Probucol
rosuvastatin
Rubidium Rb-82
Simvastatin
Sulfinpyrazone
Technetium Tc-99m sestamibi
tirofiban
TIROFIBAN HYDROCHLORIDE
Sources

Genetic Tests for Coronary Heart Disease 1

About this section

Genetic tests related to Coronary Heart Disease 1:

# Genetic test Affiliating Genes
1 Coronary Heart Disease 1 29 CX3CR1
2 Coronary Heart Disease 29
Sources

Anatomical Context for Coronary Heart Disease 1

About this section

MalaCards organs/tissues related to Coronary Heart Disease 1:

41
Heart, Endothelial, Testes, Kidney, Bone, Liver, Breast
Sources

Publications for Coronary Heart Disease 1

About this section

Articles related to Coronary Heart Disease 1:

(show top 50) (show all 32396)
# Title Authors PMID Year
1
A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. 38 8
11734540 2001
2
Genetic variants in the KIF6 region and coronary event reduction from statin therapy. 8
20886236 2011
3
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. 8
20933357 2010
4
KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. 8
20854963 2010
5
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. 8
17554300 2007
6
Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. 88
21195052 2011
7
Circulating microRNAs in patients with coronary artery disease. 88
20595655 2010
8
Gene expression profiling in whole blood of patients with coronary artery disease. 88
20528768 2010
9
Effect of statin therapy on leptin levels in patients with coronary heart disease. 9 38
20338208 2010
10
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. 9 38
20479152 2010
11
Genetic and environmental determinants of total and high-molecular weight adiponectin in families with low HDL-cholesterol and early onset coronary heart disease. 9 38
20056223 2010
12
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. 9 38
20452521 2010
13
Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. 9 38
20207770 2010
14
Demographic and cardiovascular risk factors modify association of fasting insulin with incident coronary heart disease and ischemic stroke (from the Atherosclerosis Risk In Communities Study). 9 38
20451688 2010
15
Lack of association between the cholesteryl ester transfer protein gene--TaqIB polymorphism and coronary restenosis following percutaneous transluminal coronary angioplasty and stenting: a pilot study. 9 38
19815603 2010
16
Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease. 9 38
20379055 2010
17
Does interleukin-18 or tumour necrosis factor-alpha have an independent association with the risk of coronary heart disease? Results from a prospective study in New Zealand. 9 38
20096599 2010
18
Serum adiponectin and resistin levels in major depressive disorder. 9 38
19694629 2010
19
Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease. 9 38
20339975 2010
20
Association between the interleukin-6 gene -572G/C and -597G/A polymorphisms and coronary heart disease in the Han Chinese. 9 38
20190679 2010
21
Leptin, adiponectin, their ratio and risk of Coronary Heart Disease: results from the MONICA/KORA Augsburg Study 1984-2002. 9 38
19732895 2010
22
Interrelationships of Factor VII activity and plasma leptin with insulin resistance in coronary heart disease. 9 38
19781705 2010
23
Evaluation of serum levels of C-reactive protein and lipid profiles in patients with chronic periodontitis and/or coronary heart disease in an ethnic Han population. 9 38
20213025 2010
24
Telomere length and adiposity in a racially diverse sample. 9 38
19773737 2010
25
Serum phospholipid transfer protein activity after a high fat meal in patients with insulin-treated type 2 diabetes. 9 38
20108050 2010
26
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. 9 38
20097702 2010
27
Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease. 9 38
19936703 2010
28
Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. 9 38
19717150 2010
29
Influence of genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and M1 (GSTM1) on hematological parameters. 9 38
19662515 2010
30
The common biological basis for common complex diseases: evidence from lipoprotein lipase gene. 9 38
19639021 2010
31
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. 9 38
20031199 2010
32
Association of LT-alpha Ala252Gly gene polymorphism and the genetic predisposition of coronary heart disease in Chinese. 9 38
19365711 2010
33
Screening for heart disease: C-reactive protein versus coronary artery calcium. 9 38
20014938 2010
34
Interleukin 18 and cardiovascular disease in HIV-1 infection: a partner in crime? 9 38
20216908 2010
35
Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. 9 38
19473179 2010
36
Higher level of systemic C-reactive protein is independently predictive of coronary heart disease in older community-dwelling adults: the three-city study. 9 38
20002508 2010
37
Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. 9 38
19669729 2009
38
Plasma PLTP activity is inversely associated with HDL-C levels. 9 38
19948027 2009
39
Evaluating the causal relevance of diverse risk markers: horizontal systematic review. 9 38
19892791 2009
40
Apolipoprotein E (apoE) polymorphism: a risk factor for fatal coronary sclerosis? 9 38
19733021 2009
41
Inflammatory markers and growth in South Asian and European origin infants in Britain: the Manchester Children's Growth and Vascular Health Study. 9 38
19439300 2009
42
Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. 9 38
19863872 2009
43
Association of cystatin C with ischemia in patients with coronary heart disease. 9 38
19816865 2009
44
Glucocorticoid receptor gene and depression in patients with coronary heart disease: the Heart and Soul Study-2009 Curt Richter Award Winner. 9 38
19783104 2009
45
Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study. 9 38
19922611 2009
46
Is polymorphism within eNOS gene associated with the late onset of myocardial infarction? A pilot study. 9 38
19505886 2009
47
Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias. 9 38
20031629 2009
48
P-selectin gene polymorphisms and risk of coronary heart disease among Tunisians. 9 38
19082691 2009
49
Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study. 9 38
19587389 2009
50
The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents. 9 38
19325541 2009